Your browser doesn't support javascript.
loading
T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma.
Barceló, Carla; Sisó, Pol; Maiques, Oscar; García-Mulero, Sandra; Sanz-Pamplona, Rebeca; Navaridas, Raúl; Megino, Cristina; Felip, Isidre; Urdanibia, Izaskun; Eritja, Núria; Soria, Xavier; Piulats, Josep M; Penin, Rosa M; Dolcet, Xavier; Matías-Guiu, Xavier; Martí, Rosa M; Macià, Anna.
Afiliación
  • Barceló C; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Sisó P; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Maiques O; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • García-Mulero S; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
  • Sanz-Pamplona R; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
  • Navaridas R; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Megino C; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Felip I; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Urdanibia I; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Eritja N; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Soria X; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain.
  • Piulats JM; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Penin RM; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain.
  • Dolcet X; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.
  • Matías-Guiu X; Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERON
  • Martí RM; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: marti@medicina.udl.cat.
  • Macià A; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain. Electronic address: amacia@irblleida.cat.
J Invest Dermatol ; 140(6): 1253-1265, 2020 06.
Article en En | MEDLINE | ID: mdl-31877318
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Bloqueadores de los Canales de Calcio / Protocolos de Quimioterapia Combinada Antineoplásica / Canales de Calcio Tipo T / Inhibidores de Proteínas Quinasas / Melanoma Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Bloqueadores de los Canales de Calcio / Protocolos de Quimioterapia Combinada Antineoplásica / Canales de Calcio Tipo T / Inhibidores de Proteínas Quinasas / Melanoma Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article